Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia or schizophreniform disorder;~* Duration of symptoms not longer than 60 months;~* No prior treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days;~* Between 16 and 40 years of age; and~* Current psychotic symptoms of moderate severity.~Exclusion Criteria:~* A DSM-IV Axis I diagnosis other than schizophrenia or schizophreniform;~* Documented disease of the central nervous system that can interfere with the trial assessments including, but not limited to stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic, infection;~* Acute, unstable and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension);~* A clinically significant ECG abnormality in the opinion of the investigator;~* Pregnant or breast-feeding female;~* Use of disallowed concomitant therapy;~* History of severe allergy or hypersensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Celecoxib, immune adjustor (Type: EXPERIMENTAL): Celecoxib
- Placebo (Type: PLACEBO_COMPARATOR): Placebo looks like the active drug celecoxib, with the same dose

Based on this trial design, predict the completion outcome and termination type (if applicable).